Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Neoplasms 2Colorectal Neoplasms 2Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Malignant Solid Tumor 1Carcinoma 1Advanced Cancer 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × etirinotecan pegol × Clear all
NCT02915744 2023-04-14

ATTAIN

Nektar Therapeutics

Phase 3 Completed
178 enrolled 37 charts
Breast

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT01492101 2021-06-01

BEACON

Nektar Therapeutics

Phase 3 Completed
852 enrolled 21 charts
Breast

Breast Neoplasms

NCT00802945 2018-07-09

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

Nektar Therapeutics

Phase 2 Completed
70 enrolled 15 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡